StreetInsider.com News Articles

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand

Thu, 25 Jun 2026 05:44:00 -0400

Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
This partnership marks sugemalimab's fifth international commercialization partnership, further expanding the product's global footprint.
CStone will receive an upfront payment and is eligible for regulatory and commercial milestone payments. CStone will supply sugemalimab to Arrotex and recognize a profit share arrangement.

SUZHOU, China, June 25, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX:

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages

1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability

CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.

Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights

Thu, 11 Jun 2026 02:20:00 -0400

SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.

I. Trispecific Design Rationale and Differentiated Advantages
1. Greater Potential for Long-Term Survival Benefit vs. PD-1+VEGF Combinations, with Low CTLA-4-Related Toxicity and Favorable Tolerability
CS2009 was designed to restore T-cell effector function, remodel the tumor microenvironment (TME), and enhance T-cell priming via simultaneous targeting of PD-1, VEGF, and CTLA-4, aiming to generate deeper and more durable anti-tumor immune responses.
Differentiated CTLA-4

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

Sun, 31 May 2026 20:15:00 -0400

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

Sun, 31 May 2026 20:15:00 -0400

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

Sun, 31 May 2026 20:15:00 -0400

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

Sun, 31 May 2026 20:15:00 -0400

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

Sun, 31 May 2026 20:15:00 -0400

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benefit across squamous (ORR: 87.5%) and non‑squamous (ORR: 75.0%) histologies. In the PD-L1-negative/low population (TPS ≤5%) squamous NSCLC cohort, CS2009 in combination with chemotherapy achieved an ORR of 75.0% and a DCR of 100.0%; notably, PD-L1-negative patients within this cohort achieved an ORR of 100.0%; the current efficacy readout remains immature due to the short follow‑up for most patients